Active screening for tuberculosis in high-incidence Inuit communities in Canada: a cost-effectiveness analysis.
Journal
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
ISSN: 1488-2329
Titre abrégé: CMAJ
Pays: Canada
ID NLM: 9711805
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
accepted:
14
09
2021
entrez:
2
11
2021
pubmed:
3
11
2021
medline:
7
1
2022
Statut:
ppublish
Résumé
Active screening for tuberculosis (TB) involves systematic detection of previously undiagnosed TB disease or latent TB infection (LTBI). It may be an important step toward elimination of TB among Inuit in Canada. We aimed to evaluate the cost-effectiveness of community-wide active screening for TB infection and disease in 2 Inuit communities in Nunavik. We incorporated screening data from the 2 communities into a decision analysis model. We predicted TB-related health outcomes over a 20-year time frame, beginning in 2019. We assessed the cost-effectiveness of active screening in the presence of varying outbreak frequency and intensity. We also considered scenarios involving variation in timing, impact and uptake of screening programs. Given a single large outbreak in 2019, we estimated that 1 round of active screening reduced TB disease by 13% (95% uncertainty range -3% to 27%) and was cost saving compared with no screening, over 20 years. In the presence of simulated large outbreaks every 3 years thereafter, a single round of active screening was cost saving, as was biennial active screening. Compared with a single round, we also determined that biennial active screening reduced TB disease by 59% (95% uncertainty range 52% to 63%) and was estimated to cost Can$6430 (95% uncertainty range -$29 131 to $13 658 in 2019 Can$) per additional active TB case prevented. With smaller outbreaks or improved rates of treatment initiation and completion for people with LTBI, we determined that biennial active screening remained reasonably cost-effective compared with no active screening. Active screening is a potentially cost-saving approach to reducing disease burden in Inuit communities that have frequent TB outbreaks.
Sections du résumé
BACKGROUND
Active screening for tuberculosis (TB) involves systematic detection of previously undiagnosed TB disease or latent TB infection (LTBI). It may be an important step toward elimination of TB among Inuit in Canada. We aimed to evaluate the cost-effectiveness of community-wide active screening for TB infection and disease in 2 Inuit communities in Nunavik.
METHODS
We incorporated screening data from the 2 communities into a decision analysis model. We predicted TB-related health outcomes over a 20-year time frame, beginning in 2019. We assessed the cost-effectiveness of active screening in the presence of varying outbreak frequency and intensity. We also considered scenarios involving variation in timing, impact and uptake of screening programs.
RESULTS
Given a single large outbreak in 2019, we estimated that 1 round of active screening reduced TB disease by 13% (95% uncertainty range -3% to 27%) and was cost saving compared with no screening, over 20 years. In the presence of simulated large outbreaks every 3 years thereafter, a single round of active screening was cost saving, as was biennial active screening. Compared with a single round, we also determined that biennial active screening reduced TB disease by 59% (95% uncertainty range 52% to 63%) and was estimated to cost Can$6430 (95% uncertainty range -$29 131 to $13 658 in 2019 Can$) per additional active TB case prevented. With smaller outbreaks or improved rates of treatment initiation and completion for people with LTBI, we determined that biennial active screening remained reasonably cost-effective compared with no active screening.
INTERPRETATION
Active screening is a potentially cost-saving approach to reducing disease burden in Inuit communities that have frequent TB outbreaks.
Identifiants
pubmed: 34725112
pii: 193/43/E1652
doi: 10.1503/cmaj.210447
pmc: PMC8565977
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E1652-E1659Informations de copyright
© 2021 CMA Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
CMAJ Open. 2016 Sep 16;4(3):E496-E506
pubmed: 27730114
PLoS One. 2014 Jul 17;9(7):e100975
pubmed: 25033320
Lancet Glob Health. 2019 Jan;7(1):e68-e80
pubmed: 30554764
CMAJ. 2011 Feb 22;183(3):E173-9
pubmed: 21220436
BMC Med. 2019 Feb 4;17(1):26
pubmed: 30712513
Can Commun Dis Rep. 2018 Oct 04;44(10):257-263
pubmed: 31524887
Int J Circumpolar Health. 2013 Aug 05;72:
pubmed: 23967411
Arch Intern Med. 2000 May 22;160(10):1513-21
pubmed: 10826467
BMC Public Health. 2021 Feb 3;21(1):280
pubmed: 33536003
PLoS One. 2011 Apr 04;6(4):e17601
pubmed: 21483732
Can Commun Dis Rep. 2017 Mar 02;43(3-4):77-82
pubmed: 29770069
Int J Tuberc Lung Dis. 2014 Aug;18(8):899-904
pubmed: 25199002
BMC Med. 2014 Oct 30;12:216
pubmed: 25358459
BMJ. 2018 Aug 23;362:k2738
pubmed: 30139910
BMC Public Health. 2008 Jun 05;8:201
pubmed: 18534007
Emerg Infect Dis. 2019 Apr;25(4):661-671
pubmed: 30882302
PLoS One. 2014 Jan 15;9(1):e83526
pubmed: 24454706
Can Commun Dis Rep. 2014 Mar 20;40(6):113-116
pubmed: 29769892
BMC Health Serv Res. 2019 Oct 12;19(1):690
pubmed: 31606031
BMC Health Serv Res. 2020 Apr 21;20(1):341
pubmed: 32316963
Int J Tuberc Lung Dis. 2013 Apr;17(4):432-46
pubmed: 23485377
Am J Trop Med Hyg. 2014 May;90(5):866-872
pubmed: 24615134
Can Commun Dis Rep. 2019 Feb 07;45(2-3):67-74
pubmed: 31015821